ARS Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $22,681 | $28,087 | $32,501 | $15,717 |
Gross Profit | 16,395 | 24,885 | 24,310 | 10,733 |
EBITDA | -59,748 | -41,048 | -48,799 | -44,604 |
EBIT | -60,145 | -41,465 | -51,151 | -44,883 |
Net Income | -60,618 | -41,324 | -51,151 | -44,883 |
Net Change In Cash | 22,681 | 28,087 | 32,501 | 15,717 |
Free Cash Flow | -44,946 | -43,485 | -47,244 | -39,643 |
Cash | 24,321 | 41,317 | 59,557 | 51,540 |
Basic Shares | 99,296 | 98,566 | 98,807 | 98,361 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $84,278 | $89,149 | $30 | $1,316 |
Gross Profit | 63,855 | 68,592 | 30 | -15,804 |
EBITDA | -178,081 | -3,004 | -67,447 | -35,197 |
EBIT | -179,448 | -3,083 | -67,520 | -35,516 |
Net Income | -171,298 | 7,998 | -54,365 | -34,682 |
Net Change In Cash | 84,278 | 89,149 | 30 | 1,316 |
Cost of Revenue | 150,455 | |||
Free Cash Flow | -171,205 | 12,985 | -59,441 | -40,277 |
Cash | 41,317 | 50,817 | 70,971 | 210,518 |
Basic Shares | 98,566 | 102,390 | 95,215 | 39,956 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.61 |
2025-12-31 | -$0.42 |
2025-09-30 | -$0.52 |
2025-06-30 | -$0.46 |